Aclaris Therapeutics ACRS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Aclaris Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's return on equity?
- Aclaris Therapeutics (ACRS) reported return on equity of -48.4% in Q1 2026.
- How has Aclaris Therapeutics's return on equity changed year-over-year?
- Aclaris Therapeutics's return on equity increased by 46.8% year-over-year, from -91% to -48.4%.
- What is the long-term trend for Aclaris Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's return on equity has grown at a -11.9% compound annual growth rate (CAGR), from -94.9% to -50.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.